scout
|Videos|October 6, 2022

PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME